Antimicrobial Susceptibility, Minimum Inhibitory Concentrations, and Clinical Profiles of Stenotrophomonas maltophilia Endophthalmitis
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Demographics of the Study Group
3.2. Antibiotic Susceptibility and Antimicrobial Minimum Inhibitory Concentrations (MICs)
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Chhablani, J.; Sudhalkar, A.; Jindal, A.; Das, T.; Motukupally, S.R.; Sharma, S.; Pathengay, A.; Flynn, H.W., Jr. Stenotrophomonas maltophilia endogenous endophthalmitis: Clinical presentation, antibiotic susceptibility, and outcomes. Clin. Ophthalmol. 2014, 8, 1523–1526. [Google Scholar] [CrossRef] [Green Version]
- Williams, M.A.; Gramajo, A.L.; Colombres, G.A.; Caeiro, J.P.; Juarez, C.P.; Luna, J.D. Stenotrophomonas maltophilia endophthalmitis caused by surgical equipment contamination: An emerging nosocomial infection. J. Ophthalmic. Vis. Res. 2014, 9, 383–387. [Google Scholar] [CrossRef] [PubMed]
- Lai, C.H.; Chi, C.Y.; Chen, H.P.; Chen, T.L.; Lai, C.J.; Fung, C.P.; Yu, K.W.; Wong, W.W.; Liu, C.Y. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J. Microbiol. Immunol. Infect. 2004, 37, 350–358. [Google Scholar]
- Falagas, M.E.; Kastoris, A.C.; Vouloumanou, E.K.; Rafailidis, P.I.; Kapaskelis, A.M.; Dimopoulos, G. Attributable mortality of Stenotrophomonas maltophilia infections: A systematic review of the literature. Future Microbiol. 2009, 4, 1103–1109. [Google Scholar] [CrossRef] [PubMed]
- Imoto, W.; Yamada, K.; Yamairi, K.; Shibata, W.; Namikawa, H.; Yukawa, S.; Yoshii, N.; Nakaie, K.; Hirose, A.; Koh, H. Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Intern. Med. 2020, 59, 193–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dignani, M.C.; Grazziutti, M.; Anaissie, E. Stenotrophomonas maltophilia Infections. Seminars in Respiratory and Critical Care Medicine; Thieme Medical Publishers, Inc.: New York, NY, USA, 2003; pp. 89–98. [Google Scholar]
- Wu, A.L.; Yeh, L.K.; Ma, D.H.; Chen, P.Y.; Lin, H.C.; Sun, C.C.; Tan, H.Y.; Chen, H.C.; Chen, S.Y.; Hsiao, C.H. Clinical Characteristics of Stenotrophomonas maltophilia Keratitis. Cornea 2016, 35, 795–800. [Google Scholar] [CrossRef]
- Denton, M.; Kerr, K.G. Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 1998, 11, 57–80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karakurt, A.; Abdik, O.; Sengun, A.; Karadag, R.; Saricaoglu, S.; Sarikatipoglu, H.Y.; Hasiripi, H. Stenotrophomonas maltophilia Endophthalmitis after cataract extraction. Ocul. Immunol. Inflamm. 2006, 14, 41–46. [Google Scholar] [CrossRef]
- Agarwal, A.K.; Aggarwal, K.; Samanta, R.; Angrup, A.; Biswal, M.; Ray, P.; Dogra, M.; Katoch, D.; Bansal, R.; Singh, R. Cluster endophthalmitis due to Stenotrophomonas maltophilia following intravitreal bevacizumab: Outcomes of patients from North India. Br. J. Ophthalmol. 2019, 103, 1278–1283. [Google Scholar] [CrossRef]
- Ji, Y.; Jiang, C.; Ji, J.; Luo, Y.; Jiang, Y.; Lu, Y. Post-cataract endophthalmitis caused by multidrug-resistant Stenotrophomonas maltophilia: Clinical features and risk factors. BMC Ophthalmol. 2015, 15, 14. [Google Scholar] [CrossRef] [Green Version]
- Chen, K.J.; Wang, N.K.; Sun, M.H.; Chen, T.L.; Lai, C.C.; Wu, W.C.; Tan, H.Y. Endophthalmitis caused by Stenotrophomonas maltophilia. Ophthalmic Surg Lasers Imaging 2010, 41, e555–e561. [Google Scholar] [CrossRef]
- Ferreira, M.A.; Pereira, M.L.; Dos Santos, K.V. Drug-induced tolerance: The effects of antibiotic pre-exposure in Stenotrophomonas maltophilia. Future Microbiol. 2020, 15, 497–508. [Google Scholar] [CrossRef]
- Singh, S.; Sharma, A.; Nag, V.L. Bacterial pathogens from lower respiratory tract infections: A study from Western Rajasthan. J. Family Med. Prim. Care 2020, 9, 1407–1412. [Google Scholar] [CrossRef]
- CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests, 12th ed.; Approved Standard; M02-A13; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2015. [Google Scholar]
- Horio, N.; Horiguchi, M.; Murakami, K.; Yamamoto, E.; Miyake, Y. Stenotrophomonas maltophilia endophthalmitis after intraocular lens implantation. Graefes Arch. Clin. Exp. Ophthalmol. 2000, 238, 299–301. [Google Scholar] [CrossRef]
- Horster, S.; Bader, L.; Seybold, U.; Eschler, I.; Riedel, K.G.; Bogner, J.R. Stenotrophomonas maltophilia induced post-cataract-surgery endophthalmitis: Outbreak investigation and clinical courses of 26 patients. Infection 2009, 37, 117–122. [Google Scholar] [CrossRef]
- Chen, L.; Ma, D.; She, J.; Chen, M.; Zeng, J.; Wang, J.; Zhang, G. Clinical and Optical Coherence Tomography Angiographic Features in Patients with Postcataract Stenotrophomonas maltophilia Endophthalmitis. J. Ophthalmol. 2020, 2020, 8723241. [Google Scholar] [CrossRef]
- Jung, J.W.; Kang, H.K.; Chin, H.S. Two Different Cases of Stenotrophomonas maltophilia Endophthalmitis after Cataract Surgery. J. Korean Ophthalmol. Soc. 2012, 53. [Google Scholar] [CrossRef] [Green Version]
- Chaudhry, N.A.; Flynn, H.W., Jr.; Smiddy, W.E.; Miller, D. Xanthomonas maltophilia endophthalmitis after cataract surgery. Arch. Ophthalmol. 2000, 118, 572–575. [Google Scholar] [CrossRef]
- Chang, J.S.; Flynn, H.W., Jr.; Miller, D.; Smiddy, W.E. Stenotrophomonas maltophilia endophthalmitis following cataract surgery: Clinical and microbiological results. Clin. Ophthalmol. 2013, 7, 771–777. [Google Scholar] [CrossRef] [Green Version]
- Muder, R.R. Optimizing therapy for Stenotrophomonas maltophilia. Semin Respir. Crit. Care Med. 2007, 28, 672–677. [Google Scholar] [CrossRef]
- Hanberger, H.; Nilsson, L.E. High frequency of antibiotic resistance among Gram-negative isolates in intensive care units at 10 Swedish hospitals. Clin. Microbiol. Infect. 1997, 3, 208–215. [Google Scholar] [CrossRef] [Green Version]
- García-Sáenz, M.C.; Arias-Puente, A.; Rodríguez-Caravaca, G.; Bañuelos, J.B. Effectiveness of intracameral cefuroxime in preventing endophthalmitis after cataract surgery: Ten-year comparative study. J. Cataract. Refract. Surg. 2010, 36, 203–207. [Google Scholar] [CrossRef]
- Barreau, G.; Mounier, M.; Marin, B.; Adenis, J.-P.; Robert, P.-Y. Intracameral cefuroxime injection at the end of cataract surgery to reduce the incidence of endophthalmitis: French study. J. Cataract. Refract. Surg. 2012, 38, 1370–1375. [Google Scholar] [CrossRef]
- Barbolla, R.; Catalano, M.; Orman, B.E.; Famiglietti, A.; Vay, C.; Smayevsky, J.; Centrón, D.; Piñeiro, S.A. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob. Agents Chemother. 2004, 48, 666–669. [Google Scholar] [CrossRef] [Green Version]
- Toleman, M.A.; Bennett, P.M.; Bennett, D.M.; Jones, R.N.; Walsh, T.R. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg. Infect. Dis. 2007, 13, 559–565. [Google Scholar] [CrossRef]
- Wu, R.X.; Yu, C.M.; Hsu, S.T.; Wang, C.H. Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan. J. Microbiol. Immunol. Infect. 2021. [Google Scholar] [CrossRef]
- Yue, C.; Shen, W.; Hu, L.; Liu, Y.; Zheng, Y.; Ye, Y.; Zhang, Y.; Li, J. Effects of Tigecycline Combined with Azithromycin Against Biofilms of Multidrug-Resistant Stenotrophomonas maltophilia Isolates from a Patient in China. Infect. Drug Resist. 2021, 14, 775–786. [Google Scholar] [CrossRef]
No. | Age/Sex | Cause (Days) | Systemic Diseases | Initial VA | Primary Treatment (Intravitreal Agents) | Secondary Treatment (Intravitreal Agents) | Additional Treatment (Intravitreal Agents) | Final VA |
---|---|---|---|---|---|---|---|---|
1 | 83/M | Cataract (11) | CAD | LP | TAP (VAN + CAZ) | TAP (CAZ + AMK) | HM | |
2 | 64/M | Cataract (4) | DM, HTN, ESRD | CF | TAP (VAN + CAZ) | 20/50 | ||
3 | 68/F | Cataract (3) | DM, HTN | CF | TAP (VAN + CAZ) | PPV (VAN + MOX + AMK) | PPV (MOX + CAZ) | Loss of FU |
4 | 71/F | Cataract (20) | DM, HTN | CF | TAP (VAN + CAZ) | CF | ||
5 | 57/M | IVI (3) | DM, HTN, MDD | HM | TAP (VAN + AMK) | TAP (MOX) | PPV + CE | 20/50 |
6 | 68/M | Cataract (3) | LP | PPV (VAN + AMK) | TAP (VAN + CAZ) | PPV (VAN + AMK) | CF | |
7 | 74/F | Cataract (6) | HTN, cervical cancer | 20/200 | TAP (VAN + AMK) | 20/40 | ||
8 | 76/M | Cataract (15) | DM, HTN | 20/200 | TAP (VAN + AMK) | 20/40 | ||
9 | 18/M | Cataract (29) | CF | PPV * | TAP (MOX) | TAP (MOX) | 20/200 |
No. | Levofloxacin | Moxifloxacin | SMX-TMP |
---|---|---|---|
1 | S | S | R |
2 | S | S | R |
3 | S | S | R |
4 | S | S | R |
5 | S | S | S |
6 | R | R | R |
7 | R | R | R |
8 | R | R | R |
9 | S | S | S |
MIC (μg/mL) | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 12 | 32 | 256 |
---|---|---|---|---|---|---|---|---|---|---|
Levofloxacin | 3 | 2 a | 3 b | |||||||
Moxifloxacin | 2 | 3 a | 3 b | |||||||
Gatifloxacin | 1 | 3 a | 1 | 1 | 2 b | |||||
Tigecycline | 1 | 2 | 2 a | 3 b | ||||||
Cefuroxime | 8 ab | |||||||||
SMX-TMP | 1 | 7 ab | ||||||||
Amikacin | 1 | 4 a | 2 | 1 b | ||||||
Ceftazidime | 1 | 7 ab |
No. | Author | Nationality | Year | No. of Eyes | Etiology (No. of Eyes) | Initial VA Worse Than 20/200 (%) | Fluoroquinolone Susceptibility (No.,%) | PPV | Final VA Worse Than 20/200 (%) |
---|---|---|---|---|---|---|---|---|---|
1 | Chauhdry et al. [20] | USA | 1996–1999 | 4 | Cataract | 3 (75) | 2 | 1 (25%) | |
2 | Chang et al. [21] | USA | 1996–2005 | 8 | Cataract | 6 (75) | Levofloxacin (3, 38%) | 3 | 2 (33%) |
3 | Chen et al. [12] | Taiwan | 1998–2007 | 6 | Trauma (2), Cataract (2), PK (1), Vitreous lavage (1) | 6 (100) | Levofloxacin (2/2, 100%) Moxifloxacin (2/2, 100%) Ciprofloxacin (3/4, 75%) | 4 | 2 (33%) |
4 | Horio et al. [16] | Japan | 1999 | 2 | Cataract | 2 (100) | 2 | 2 (100%) | |
5 | Horster et al. [17] | Germany | 1999 | 26 | Cataract | 13 * (50) | 21 | 5 * (19%) | |
6 | Lai et al. [3] | Hongkong | 2001 | 1 | Trauma | 1 (100) | 1 | 0 | |
7 | Karakurt et al. [9] | Turkey | 2004 | 6 | Cataract (5) Cataract+ Trab+ PPV (1) | 6 (100) | 2 | 2 (33%) | |
8 | Chhablani et al. [1] | India | 2007–2012 | 4 | Endogenous | 4 (100) | Gatifloxacin (3, 75%) Moxifloxacin (4, 100%) | 4 | 1 (25%) |
9 | Ji et al. [11] | China | 2010–2011 | 14 | Cataract | 10 (71) | Levofloxacin (8, 57%) | 11 | 1 (7%) |
10 | Williams et al. [2] | Argentina | 2014 | 3 | Cataract | 2 (67) | 2 | 1 (33%) | |
11 | Agarwal et al. [10] | India | 2016 | 28 | IVI | 23 (82) | Levofloxacin (28, 100%) | 23 | 1 (4%) |
12 | Chen et al. [18] | China | 2019 | 4 | Cataract | 4 (100) | Levofloxacin (3, 75%) | 4 | 0 |
13 | Ho et al. (current study) | Taiwan | 2011–2019 | 9 | Cataract (8), IVI (1) | 6 (75) | Levofloxacin (5, 63%) Moxifloxacin (5, 63%) | 4 | 3 (38%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ho, M.-C.; Hsiao, C.-H.; Sun, M.-H.; Hwang, Y.-S.; Lai, C.-C.; Wu, W.-C.; Chen, K.-J. Antimicrobial Susceptibility, Minimum Inhibitory Concentrations, and Clinical Profiles of Stenotrophomonas maltophilia Endophthalmitis. Microorganisms 2021, 9, 1840. https://doi.org/10.3390/microorganisms9091840
Ho M-C, Hsiao C-H, Sun M-H, Hwang Y-S, Lai C-C, Wu W-C, Chen K-J. Antimicrobial Susceptibility, Minimum Inhibitory Concentrations, and Clinical Profiles of Stenotrophomonas maltophilia Endophthalmitis. Microorganisms. 2021; 9(9):1840. https://doi.org/10.3390/microorganisms9091840
Chicago/Turabian StyleHo, Ming-Chih, Ching-Hsi Hsiao, Ming-Hui Sun, Yih-Shiou Hwang, Chi-Chun Lai, Wei-Chi Wu, and Kuan-Jen Chen. 2021. "Antimicrobial Susceptibility, Minimum Inhibitory Concentrations, and Clinical Profiles of Stenotrophomonas maltophilia Endophthalmitis" Microorganisms 9, no. 9: 1840. https://doi.org/10.3390/microorganisms9091840